Literature DB >> 11150594

Regulation of T helper type 2 cell immunity by interleukin-4 and interleukin-13.

A N McKenzie1.   

Abstract

Type 2 cytokine responses are typical of immune reactions to parasitic helminth infections, allergies, and asthma, and are characterised by the production of the cytokines interleukin (IL)-4, IL-5, IL-9, and IL-13 by subsets of T helper type 2 (Th2) cells. These cytokines form a complex network of molecular and cellular interactions that mediate protective immunity to worm infection, but also induce inappropriate inflammatory responses to allergic challenge. Although considerable attention has been given to the roles played by IL-4 in Th2 responses, the identification of the related cytokine IL-13 has led to a re-evaluation of how these two molecules combine in the generation of Th2 immunity. Recent reports have highlighted that in certain challenges, IL-4 and IL-13 act in combination to ensure the rapid onset of a Th2-like response. However, these studies have also identified specific responses that are attributable to the individual cytokines. For example, IL-13 appears to play a more dominant role than IL-4 in the expulsion of certain gastrointestinal parasites. In contrast, following schistosome infection, IL-13 induces a detrimental hepatic fibrosis, while IL-4 protects against endotoxemia. These results emphasise the complexity of the cytokine network, and highlight the care that needs to be taken when designing therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11150594     DOI: 10.1016/s0163-7258(00)00088-7

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  18 in total

1.  Th2 cytokines IL-4 and IL-13 downregulate paxillin expression in bronchial airway epithelial cells.

Authors:  Gail Ramirez-Icaza; Kamal A Mohammed; Najmunnisa Nasreen; Robert D Van Horn; Joyce A Hardwick; Kerry L Sanders; Jun Tian; Carlos Ramirez-Icaza; Mary T Johnson; Veena B Antony
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

2.  Association of 24 bp duplication of human CHIT1 gene with asthma in a heterozygous population of north India: a case-control study.

Authors:  Shweta Sinha; Jagtar Singh; Surinder Kumar Jindal; Niti Birbian; Neha Singla
Journal:  Lung       Date:  2014-06-14       Impact factor: 2.584

Review 3.  Immune regulation during allergic bronchopulmonary mycosis: lessons taught by two fungi.

Authors:  Shikha Arora; Gary B Huffnagle
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 4.  Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis.

Authors:  Claudia Jakubzick; Steven L Kunkel; Raj K Puri; Cory M Hogaboam
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

5.  Signal transducer and activator of transcription 6 polymorphism and asthma risk: a meta-analysis.

Authors:  Bin Li; Wei Nie; Qiong Li; Hongchao Liu; Shiyuan Liu
Journal:  Int J Clin Exp Med       Date:  2013-09-01

6.  Interleukin-4 receptor alpha chain and STAT6 signaling inhibit gamma interferon but not Th2 cytokine expression within schistosome granulomas.

Authors:  Ahmed Metwali; Arthur Blum; David E Elliott; Joel V Weinstock
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

Review 7.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

8.  Interleukin-13 fusion cytotoxin arrests Schistosoma mansoni egg-induced pulmonary granuloma formation in mice.

Authors:  Claudia Jakubzick; Steven L Kunkel; Bharat H Joshi; Raj K Puri; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

Review 9.  TH2 cell development and function.

Authors:  Jennifer A Walker; Andrew N J McKenzie
Journal:  Nat Rev Immunol       Date:  2017-10-30       Impact factor: 53.106

10.  Prolonged allergen challenge in mice leads to persistent airway remodelling.

Authors:  S J McMillan; C M Lloyd
Journal:  Clin Exp Allergy       Date:  2004-03       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.